Immunoscape
Singapore, SG · Founded 2016 · 22 employees on LinkedIn · 1 known investors
Find your way into Immunoscape
Sign up to see every warm intro you have to Immunoscape
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunoscape team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ImmunoScape is a Singapore-based biotechnology company developing high-throughput immune profiling and therapeutic T cell receptor discovery platforms for immunotherapy and cancer treatment. The company was spun off from Singapore's A*STAR research institute and serves the immunotherapy and oncology sectors.
Founders & leadership
Immunoscape was founded in 2016 by Michael Fehlings, PhD, Evan Newell, PhD, and Alessandra Nardin, DVM.
MF
Michael Fehlings, PhDCo-founder, Chief Executive Officer
EN

Evan Newell, PhDCo-founder/Advisor
AN
Alessandra Nardin, DVMCo-founder, Vice President Strategy
Investors · 1
Anzu Partnerslisted by Anzu PartnersBillerica
How we know: Anzu Partners's portfolio page · a partner's Signal profile · Not right? Tell us
Frequently asked questions
- What does Immunoscape do?
- ImmunoScape is a Singapore-based biotechnology company developing high-throughput immune profiling and therapeutic T cell receptor discovery platforms for immunotherapy and cancer treatment. The company was spun off from Singapore's A*STAR research institute and serves the immunotherapy and oncology sectors.
- Who founded Immunoscape?
- Immunoscape was founded by Michael Fehlings, PhD, Evan Newell, PhD, Alessandra Nardin, DVM in 2016.
- Who are Immunoscape's investors?
- Immunoscape's investors include Anzu Partners.
- Where is Immunoscape headquartered?
- Immunoscape is headquartered in Singapore, SG.

